Overview
Microbix makes biotherapeutic drugs, vaccines, and infectious disease diagnostics for multinational manufacturers. The company's pipeline includes leading generic drug candidate ThromboClear for the treatment of coronary artery thrombosis and the FDA-approved drug urokinase, used to treat pulmonary embolism. Microbix has also submitted patents for its Sperm Sexing Technology, which enables livestock producers to predetermine offspring gender prior
...
Read More to conception. In 2008 Microbix entered into an agreement with China to build one of the world's largest influenza manufacturing plants to produce flu vaccines.
Read Less
Read More to conception. In 2008 Microbix entered into an agreement with China to build one of the world's largest influenza manufacturing plants to produce flu vaccines.
Read Less
Cameron L. Groome
See more contacts
Medical and Diagnostic Laboratories
,
Ambulatory Health Care Services
,
Health Care and Social Assistance
,
Biological laboratory
Child Care Services
,
Community Food and Housing, and Emergency and Other Relief Services
,
Continuing Care Retirement Communities and Assisted Living Facilities for the Elderly
,
General Medical and Surgical Hospitals
,
Home Health Care Services
,
Individual and Family Services
,
Nursing Care Facilities (Skilled Nursing Facilities)
,
Offices of Dentists
View more , Offices of Other Health Practitioners , Offices of Physicians , Other Ambulatory Health Care Services , Other Residential Care Facilities , Outpatient Care Centers , Psychiatric and Substance Abuse Hospitals , Residential Intellectual and Developmental Disability, Mental Health, and Substance Abuse Facilities , Specialty (except Psychiatric and Substance Abuse) Hospitals Vocational Rehabilitation Services
View fewer
View more , Offices of Other Health Practitioners , Offices of Physicians , Other Ambulatory Health Care Services , Other Residential Care Facilities , Outpatient Care Centers , Psychiatric and Substance Abuse Hospitals , Residential Intellectual and Developmental Disability, Mental Health, and Substance Abuse Facilities , Specialty (except Psychiatric and Substance Abuse) Hospitals Vocational Rehabilitation Services
View fewer
?
?
?
Actual
?
Actual
$18.86 million
Actual
53.77%
$38
SEP
?
?
Toronto:MBX
Contacts
Get in Touch with 14 Principals* and 48 Contacts
-
Cameron L. GroomePresident and Member of the Board of Directors
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of September 30, 2024 (12 month period) in USD
Annual Revenue 2024
$18.86 million
USD
Actual
1 USD = 1.3463 CAD
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $3 | -$1 | $3 |
| Net Investing Cash | -$1 | -$1 | -$2 |
| Net Financing Cash | -$1 | $0 | $2 |
| Net Change in Cash | $1 | -$1 | $3 |
| Cash at Beginning of Period | $9 | $10 | $7 |
| Cash at End of Period | $10 | $9 | $10 |
| Capital Expenditure | -$1 | -$1 | -$2 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $10 | $9 | $10 |
| Accounts Receivable | $3 | $3 | $2 |
| Inventories | $5 | $4 | $4 |
| Other Current Assets | $0 | $1 | $0 |
| Asset Summary | |||
| Total Current Assets | $18 | $17 | $17 |
| Tangible Fixed Assets | $7 | $7 | $7 |
| Intangible Assets | $3 | $3 | $1 |
| Total Assets | $38 | $36 | $33 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $ | $ | $ |
| Short-Term Debt | $0 | $0 | $0 |
| Other Current Liabilities | $2 | $3 | $2 |
| Liability Summary | |||
| Total Current Liabilities | $3 | $3 | $2 |
| Long-Term Debt | $4 | $4 | $3 |
| Other Long-Term Liabilities | $0 | $0 | $ |
| Total Liabilities | $7 | $8 | $6 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $36 | $36 | $37 |
| Retained Earnings | -$25 | -$27 | -$27 |
| Equity Summary | |||
| Total Equity | $21 | $18 | $19 |
| Shares Outstanding | 135,674,136 | 136,853,373 | 138,991,373 |